Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation

被引:17
作者
Gottfredsson, M
Vredenburgh, JJ
Xu, JP
Schell, WA
Perfect, JR
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Hematol Oncol, Durham, NC 27710 USA
[3] Duke Univ, Dept Microbiol, Durham, NC 27710 USA
关键词
candidemia; breast carcinoma; autologous bone marrow transplantation; chemotherapy; mortality; DNA fingerprinting;
D O I
10.1002/cncr.11470
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. invasive fungal infections, including candidemia, pose a major threat to patients with impaired immune defenses, including bone marrow transplantation (BMT) recipients. During 1992-1997, 845 women with multiple lymph node positive or metastatic breast carcinoma underwent high-dose chemotherapy (HDC) and subsequent autologous BMT at Duke University Medical Center. No systemic antifungal prophylaxis was administered. The purpose of the current study was to evaluate the risk and long-term outcome of candidemia in this patient population. METHODS. Clinical data were collected on patients with candidemia, and a group of age-matched control patients were identified who underwent HDC and EMT for breast carcinoma in the same time period. The difference in crude mortality between these two groups was used to calculate the attributable mortality of candidemia. The genetic relatedness of the fungal blood stream isolates was investigated by DNA fingerprinting. Antifungal susceptibility testing was performed using serial microdilution. RESULTS. Twenty-nine of 845 women developed candidemia (3.4%). The crude mortality of women with candidemia was 35% at 90 days after transplantation but 11% among women in the matched control group who were without infection (P = 0.01), for an attributable mortality rate of 24%. The most common pathogen was Candida tropicalis (50%), followed by Candida albicans (23%). The mortality was highest for women who were infected with C. albicans, followed by C. tropicalis, and other Candida species (P = 0.037). DNA fingerprinting of the yeasts revealed genetic heterogeneity in all species. However, 9 of 15 C. tropicalis isolates had identical DNA fingerprint profiles, suggesting spread of this genotype from a common source. All yeast isolates were susceptible to amphotericin B, and 20 of 30 isolates were susceptible to less than or equal to 8 mug/mL of fluconazole. CONCLUSIONS. Candidemia was relatively infrequent after HDC and autologous BMT in women with for multiple lymph node positive or metastatic breast carcinoma. This was true even in the absence of systemic antifungal prophylaxis. The mortality attributable to candidemia in this patient population was 24% and was higher among patients who were infected by C. albicans compared with patients who were infected by other Candida, non-albicans species. (C) 2003 American Cancer Society.
引用
收藏
页码:24 / 30
页数:7
相关论文
共 32 条
[1]   Candida krusei fungemia -: An escalating serious infection in immunocompromised patients [J].
Abbas, J ;
Bodey, GP ;
Hanna, HA ;
Mardani, M ;
Girgawy, E ;
Abi-Said, D ;
Whimbey, E ;
Hachem, R ;
Raad, I .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) :2659-2664
[2]   EXPERIMENTAL HEMATOGENOUS CANDIDIASIS CAUSED BY CANDIDA-KRUSEI AND CANDIDA-ALBICANS - SPECIES-DIFFERENCES IN PATHOGENICITY [J].
ANAISSIE, E ;
HACHEM, R ;
KTINU, C ;
STEPHENS, C ;
BODEY, GP .
INFECTION AND IMMUNITY, 1993, 61 (04) :1268-1271
[3]  
[Anonymous], 1981, Statistical Tables
[4]   Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer [J].
Barton, TD ;
Collis, T ;
Stadtmauer, E ;
Schuster, MG .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :391-395
[5]   The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer [J].
Bodey, GP ;
Mardani, M ;
Hanna, HA ;
Boktour, M ;
Abbas, J ;
Girgawy, E ;
Hachem, RY ;
Kontoyiannis, DP ;
Raad, II .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (05) :380-385
[6]   Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice [J].
Brieland, J ;
Essig, D ;
Jackson, C ;
Frank, D ;
Loebenberg, D ;
Menzel, F ;
Arnold, B ;
DiDomenico, B ;
Hare, R .
INFECTION AND IMMUNITY, 2001, 69 (08) :5046-5055
[7]   CLOTRIMAZOLE (BAY B 5097) - IN-VITRO AND CLINICAL PHARMACOLOGICAL STUDIES [J].
BURGESS, MA ;
BODEY, GP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1972, 2 (06) :423-&
[8]   GASTROINTESTINAL COLONIZATION AND SYSTEMIC DISSEMINATION BY CANDIDA-ALBICANS AND CANDIDA-TROPICALIS IN INTACT AND IMMUNOCOMPROMISED MICE [J].
DEREPENTIGNY, L ;
PHANEUF, M ;
MATHIEU, LG .
INFECTION AND IMMUNITY, 1992, 60 (11) :4907-4914
[9]   SEQUENTIAL PROPHYLACTIC ORAL AND EMPIRIC ONCE-DAILY PARENTERAL ANTIBIOTICS FOR NEUTROPENIA AND FEVER AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT [J].
GILBERT, C ;
MEISENBERG, B ;
VREDENBURGH, J ;
ROSS, M ;
HUSSEIN, A ;
PERFECT, J ;
PETERS, WP .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :1005-1011
[10]   CLINICAL-FEATURES AND ANALYSIS OF RISK-FACTORS FOR INVASIVE CANDIDAL INFECTION AFTER MARROW TRANSPLANTATION [J].
GOODRICH, JM ;
REED, EC ;
MORI, M ;
FISHER, LD ;
SKERRETT, S ;
DANDLIKER, PS ;
KLIS, B ;
COUNTS, GW ;
MEYERS, JD .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (04) :731-740